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1. INTRODUCTION {#cam42514-sec-0001}
===============

Cigarette smoking and alcohol drinking are serious public health issues. WHO has estimated that 8.7% of global deaths in 2004 and 3.7% of disability‐adjusted life years (DALYs) were attributable to cigarette smoking.[1](#cam42514-bib-0001){ref-type="ref"} Moreover, alcohol drinking caused 3.6% of deaths and 4.4% of DALYs. An accurate understanding of the risk of cigarette‐ and alcohol‐related diseases in each population will allow the current impact of these practices to be identified. In addition, this understanding of risk will also be useful in predicting the effect of intervention, because cigarette smoking and alcohol drinking are modifiable risk factors.

Both cigarette smoking and alcohol drinking have been established as major risk factors for esophageal cancer.[2](#cam42514-bib-0002){ref-type="ref"}, [3](#cam42514-bib-0003){ref-type="ref"}, [4](#cam42514-bib-0004){ref-type="ref"}, [5](#cam42514-bib-0005){ref-type="ref"}, [6](#cam42514-bib-0006){ref-type="ref"} Biological evidence supports the idea that tobacco extracts and ethanol have an interactive effect in carcinogenesis.[7](#cam42514-bib-0007){ref-type="ref"}, [8](#cam42514-bib-0008){ref-type="ref"} To support this, several, but not all, case‐control studies showed that cigarette smoking and alcohol drinking have an interactive effect on esophageal cancer risk.[9](#cam42514-bib-0009){ref-type="ref"}, [10](#cam42514-bib-0010){ref-type="ref"}, [11](#cam42514-bib-0011){ref-type="ref"}, [12](#cam42514-bib-0012){ref-type="ref"}, [13](#cam42514-bib-0013){ref-type="ref"}, [14](#cam42514-bib-0014){ref-type="ref"}, [15](#cam42514-bib-0015){ref-type="ref"}, [16](#cam42514-bib-0016){ref-type="ref"}, [17](#cam42514-bib-0017){ref-type="ref"}, [18](#cam42514-bib-0018){ref-type="ref"}, [19](#cam42514-bib-0019){ref-type="ref"}, [20](#cam42514-bib-0020){ref-type="ref"}, [21](#cam42514-bib-0021){ref-type="ref"}, [22](#cam42514-bib-0022){ref-type="ref"}, [23](#cam42514-bib-0023){ref-type="ref"}, [24](#cam42514-bib-0024){ref-type="ref"}, [25](#cam42514-bib-0025){ref-type="ref"} In contrast, four cohort studies and a case‐cohort study have failed to replicate this interactive effect of two factors [26](#cam42514-bib-0026){ref-type="ref"}, [27](#cam42514-bib-0027){ref-type="ref"}, [28](#cam42514-bib-0028){ref-type="ref"}, [29](#cam42514-bib-0029){ref-type="ref"}, [30](#cam42514-bib-0030){ref-type="ref"}, [31](#cam42514-bib-0031){ref-type="ref"} (Table [1](#cam42514-tbl-0001){ref-type="table"}). Therefore, although the interaction between smoking and alcohol drinking has been recognized as an answered question,[32](#cam42514-bib-0032){ref-type="ref"} this question remained an unanswered one warranting a further investigation in prospective cohort studies.

###### 

Studies reporting joint effect of smoking and alcohol for esophageal cancer

  Study                 Ref      Journal                   Year   Country                      Study Design   Category of smoking                           Category of drinking                              RR of heaviest smoking and CI   RR of heaviest drinking and CI   Joint effect of heaviest smoking and drinking   Statistical test of multiplicative interaction       Statistical test of additive interaction              
  --------------------- -------- ------------------------- ------ ---------------------------- -------------- --------------------------------------------- ------------------------------------------------- ------------------------------- -------------------------------- ----------------------------------------------- ---------------------------------------------------- ------------------------------------------------ ---- ----
  Kinjo et al.          \[26\]   J Epidemiol               1998   Japan                        Cohort         Never/Current                                 Non‐daily/daily                                   1.6 (1.1‐2.1)                   1.0 (0.4‐2.0)                    3.9 (2.7‐5.4)                                   NE                                                   NE                                                    
  Fan et al.            \[27\]   Nutr Cancer               2000   China                        Cohort         Number of years of smoking                    Number of drinks per day                          2.18 (0.80‐5.92)                3.86 (0.86‐17.26)                8.00 (3.36‐19.05)                               *P* = .99                                            NE                                                    
  Ishiguro et al.       \[28\]   Cancer lett               2009   Japan                        Cohort         Light/heavy                                   Light/heavy                                       2.31 (1.58‐3.38)                2.96 (2.01‐4.34)                 6.12 (4.13‐9.05)                                *P*  = .70                                           NE                                                    
  Weikert et al.        \[29\]   Int J Cancer              2009   Europe                       Cohort         Never/ex/current                              Lifetime alcohol intake                           5.76 (3.20‐10.36)               1.71 (0.38‐7.67)                 22.86 (12.27‐42.60)                             *P*  = .27                                           NE                                                    
  Yaegashi et al.       \[30\]   Asian Pac J Cancer Prev   2014   Japan                        Cohort         Smoking status                                Drinking status                                   0.80 (0.15‐4.15)                0.64 (0.07‐5.96)                 6.05 (1.87‐19.60)                               NE                                                   NE                                                    
  Steevens et al.       \[31\]   Gut                       2010   Nether‐lands                 Case‐cohort    never/former/current                          gram ethanol/day                                  1.70 (0.72‐4.05)                3.74 (1.25‐11.20)                8.05 (3.89‐16.60)                               *P*  = .65                                           NE                                                    
  De Stefani et al.     \[9\]    Cancer Res                1990   Uruguay                      Case‐control   Cigarettes per day                            ml per day                                        3.10                            6.70                             22.60                                                                                                                                                 NE   NE
  Chongsuvivatwong      \[10\]   J Gastroenterol Hepatol   1990   Thailand                     Case‐control   Never/ever                                    Never/Ever                                        1.65 (0.66‐4.11)                4.73 (0.53‐42.1)                 5.68 (2.14‐15.1)                                NE                                                   NE                                                    
  Brown et al.          \[11\]   J Natl Cancer Inst        1994   America                      Case‐control   Light/heavy                                   Drinks per week                                   4.5 (1.4‐14.6)                  31.0 (9.8‐98.5)                  149.2 (39.2‐567.4)                              Described as "not significantly different" in text   Described as "statistically different" in text        
  Castellsague et al.   \[12\]   Int J Cancer              1999   South America                Case‐control   Average number of cigarettes smoked per day   Average amount of pure ethanol consumed per day   6.84                            14.13                            50.85                                           *P*  = .20                                           NE                                                    
  Zambon et al.         \[13\]   Int J Cancer              2000   Italy                        Case‐control   Smoking habit (cig/day)                       Alcohol intake (drinks/week)                      6.97 (3.22‐15.06)               28.48 (10.09‐80.39)              130.32 (15.20‐980.10)                           *P*  = .27                                           NE                                                    
  Znaor et al.          \[14\]   Int J Cancer              2003   India                        Case‐control   Never/Ever                                    Never/Ever                                        3.57 (2.51‐5.06)                3.41 (1.46‐7.99)                 7.33 (5.06‐10.62)                               *P*  = .62                                           NE                                                    
  Lee et al.            \[15\]   Int J Cancer              2005   Taiwan                       Case‐control   never/ever                                    never/ever                                        2.4 (1.1‐5.0)                   1.4 (0.4‐4.5)                    23.3 (12.2‐44.5)                                *P*  = .003                                          NE                                                    
  Wu et al.             \[16\]   Eur J Clin Invest         2006   China                        Case‐control   Never/Ever                                    Never/Ever                                        6.5 (1.9‐29.80)                 23.3 (4.3‐142.2)                 108.0 (35.1‐478.0)                                                                                   NE                                                    
  Hashibe et al.        \[17\]   Int J Cancer              2007   Central and Eastern Europe   Case‐control   No/Yes                                        No/Yes                                            0.71 (0.07‐7.00)                0.96 (0.28‐3.28)                 6.42 (2.03‐20.30)                               9.41 (0.88‐100.27)*P * \< 0.01                       NE                                                    
  Lee et al.            \[18\]   Int J Cancer              2007   Taiwan                       Case‐control   never/ever                                    never/ever                                        1.9 (1.2‐3.2)                   2.3 (1.2‐4.4)                    19.7 (12.4‐31.3)                                *P*  = .0001                                         8.2 (4.1‐16.5)                                        
  Lee et al.            \[19\]   Int J Cancer              2008   Taiwan                       Case‐control   No/Yes                                        No/Yes                                            1.2 (0.2‐7.7)                   3.7 (0.5‐27.1)                   45.0 (12.0‐168.3)                               *P*  = .042                                          NE                                                    
  Tanaka et al.         \[20\]   Gut                       2010   Japan                        Case‐control   never/ever                                    never/ever                                        4.5 (1.3‐15.9)                  1.5 (0.7‐3.3)                    5.0 (2.5‐10.1)                                  *P* \<.001                                           NE                                                    
  Canova et al.         \[21\]   Tumori                    2010   Italy                        Case‐control   Pack year                                     average drinks/day                                3.36 (1.39‐8.15)                1.65 (0.60‐4.56)                 34.81 (14.69‐82.50)                             *P*  = .0012                                         NE                                                    
  Chen et al.           \[22\]   Exp Ther Med              2010   China                        Case‐control   Never/Ever                                    Never/Ever                                        6.2                             19.5                             43.8                                            beta = ‐1.01 (‐1.46 ‐ −0.56)                         NE                                                    
  Wu et al.             \[23\]   Cancer Causes Control     2011   China                        Case‐control   Never/Ever                                    Never/Ever                                        1.20 (0.96‐1.51)                1.03 (0.80‐1.32)                 2.10 (1.72‐2.56)                                *P* \<.001                                           NE                                                    
  Anantharaman et al.   \[24\]   Oral Oncol                2011   Europe                       Case‐control   Never/Ever                                    Never/Ever                                        2.68 (1.69‐4.24)                3.14 (1.50‐6.55)                 7.86 (4.81‐12.86)                               0.93 (0.42‐2.03)                                     NE                                                    
  Lin et al.            \[25\]   Int J Cancer              2015   China                        Case‐control   Never/Ever                                    Never/Ever                                        2.26 (1.31‐3.92)                1.28 (8.00‐2.04)                 5.58 (3.88‐8.03)                                NE                                                   NE                                                    

Abbreviations: Ref, reference number; RR, relative risk; CI, confidence interval; NE, not estimated
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There are two important points in evaluating the interaction between cigarette smoking and alcohol drinking for esophageal cancer risk in cohort studies. First, only two studies reported the magnitude of interaction for esophageal cancer risk.[15](#cam42514-bib-0015){ref-type="ref"}, [17](#cam42514-bib-0017){ref-type="ref"} However, this information is necessary if the attribution of cigarette smoking and alcohol drinking is to be estimated. Greater statistical power is required to assess the relevant magnitude of interaction on esophageal cancer risk. Second, interaction between two exposures should be assessed both multiplicatively and additively. Previous evaluations often measured the interaction on a multiplicative scale, because this measure could be obtained calculated by most software packages. In contrast, interaction was rarely measured on an additive scale because of the additional work required to estimate measures of additive interaction.[15](#cam42514-bib-0015){ref-type="ref"}, [33](#cam42514-bib-0033){ref-type="ref"}, [34](#cam42514-bib-0034){ref-type="ref"} Nevertheless, additive interaction is a relevant measure for assessing the public health significance of interaction, because tests for additive interaction sometimes have greater power to detect an interaction than tests for multiplicative interaction.[34](#cam42514-bib-0034){ref-type="ref"} In addition, interaction on an additive scale might be more appropriate than multiplicative interaction when estimating the impact of interventions.[35](#cam42514-bib-0035){ref-type="ref"}, [36](#cam42514-bib-0036){ref-type="ref"} Furthermore, type of interaction might suggest theory of carcinogenesis. Under a multistage theory of carcinogenesis, additivity of action of two factors might occur if each act independently on the same stage, whereas multiplicativity of action might be observed if each factor acts on a different carcinogenic stage.[37](#cam42514-bib-0037){ref-type="ref"} In this context, additive and multiplicative interactions represent a way of quantifying departure from these two hypotheses about the effect of the factors on the carcinogenic process. Accordingly, interaction between cigarette smoking and alcohol drinking for esophageal cancer risk should be assessed quantitatively on both an additive and multiplicative scale.

Here, we conducted a pooled analysis using large‐scale population‐based cohort studies in Japan to accurately estimate the joint effect of cigarette smoking and alcohol drinking on esophageal cancer risk.

2. METHOD {#cam42514-sec-0002}
=========

2.1. Study population {#cam42514-sec-0003}
---------------------

In 2006, the Research Group for the Development and Evaluation of Cancer Prevention Strategies in Japan began pooling original data from major cohort studies to evaluate the association between lifestyle and major cancers in Japanese, along with systematic reviews of the relevant literature. Topics for the pooled analysis were determined based on their scientific and public health importance, as determined by discussions among group members. For the present analysis, the following a priori inclusion criteria were established: population‐based cohort studies conducted in Japan; study initiation between the mid‐1980s and mid‐1990s; inclusion of more than 30 000 participants; and baseline collection of information on diet, alcohol intake, and smoking.

Subjects in this study were from eight representative large‐scale cohort studies in Japan: (a) the Japan Public Health Center‐based Prospective Study (JPHC‐I),[38](#cam42514-bib-0038){ref-type="ref"} (b) JPHC‐II,[38](#cam42514-bib-0038){ref-type="ref"} (c) the Japan Collaborative Cohort Study (JACC),[39](#cam42514-bib-0039){ref-type="ref"} (d) the Ohsaki National Health Insurance Cohort Study (OHSAKI),[40](#cam42514-bib-0040){ref-type="ref"} (e) the Miyagi Cohort Study (MIYAGI),[41](#cam42514-bib-0041){ref-type="ref"} (f) the Three‐Prefecture Cohort Study, Miyagi (3‐pref MIYAGI),[42](#cam42514-bib-0042){ref-type="ref"} (g) the Three‐Prefecture Cohort Study, Aichi (3‐pref AICHI),[42](#cam42514-bib-0042){ref-type="ref"} and (h) the Takayama Study (TAKAYAMA)[43](#cam42514-bib-0043){ref-type="ref"} (Table [1](#cam42514-tbl-0001){ref-type="table"}). These studies all commenced after the mid‐1980s and each enrolled more than 30 000 participants. Residence status in each study, including survival, was confirmed through the residential registry. Female subjects were excluded because the numbers of incident esophageal cancer cases, cigarette smokers, and alcohol drinkers were too small to analyze. Variables used in data linkage, censoring criteria, and the method used to obtain information on cancer incidence in each study are provided in Table [S1](#cam42514-sup-0001){ref-type="supplementary-material"}. Study quality was assessed using Newcastle‐Ottawa Scale. The scores were eight in all the cohort studies.[44](#cam42514-bib-0044){ref-type="ref"} Each study was approved by its relevant institutional ethics review board.

2.2. Assessment of exposure {#cam42514-sec-0004}
---------------------------

Exposure data were retrieved from self‐administered questionnaire surveys conducted at baseline in each study. For cigarette smoking status, subjects were categorized as never or ever smokers. Cumulative cigarette smoking was evaluated using pack‐years, calculated by multiplying the number of packs consumed per day by the number of years of smoking, then classified into the three categories of 0, 0\< and ≤40, and \>40 pack‐years. For alcohol drinking status, subjects were categorized as never or ever drinkers. Alcohol drinking was categorized by amount as \<23, 23 to \<46, or ≥46 ethanol g/day. The cut point of 23 g ethanol was defined on the basis that some questionnaires collected consumption data in terms of one "go" (180 mL), a term for a Japanese sake equivalent, which contains 23 g ethanol.

2.3. Assessment of outcome {#cam42514-sec-0005}
--------------------------

The individual studies identified esophageal cancer cases via local cancer registries or direct access to major local hospitals. Information on cancer diagnosis was collected for the whole population and was coded using the International Classification of Diseases for Oncology, Third Edition (ICD‐O3).[45](#cam42514-bib-0045){ref-type="ref"} Study outcome was defined as the incidence of esophageal cancer (ICD‐9:150.0‐150.9,[46](#cam42514-bib-0046){ref-type="ref"} ICD‐10[46](#cam42514-bib-0046){ref-type="ref"} or ICD‐O3: C15.0‐C15.9) during the follow‐up period of each study. Participants were followed from the date of completion of the baseline questionnaire (JPHC‐I and ‐II: 1990‐1994, JACC: 1998‐1990, MIYAGI: 1990, 3‐pref. MIYAGI: 1984, OHSAKI: 1994, 3‐pref. AICHI: 1985, and TAKAYAMA: 1992), date of death, date of loss to follow‐up, or date of diagnosis of esophageal cancer, whichever occurred first.

2.4. Statistical analysis {#cam42514-sec-0006}
-------------------------

The analysis was based on a three‐step approach: first, Cox regression models were used in each study to obtain estimates of the effect of smoking and drinking; second, these study‐specific results were combined through meta‐analysis; and finally, the summary effects were used to compute various measures of interaction.

2.5. Estimation of the study‐specific effects of smoking and alcohol consumption {#cam42514-sec-0007}
--------------------------------------------------------------------------------

In the context of categorical variables (here, smoking and alcohol consumption), the calculation of interaction measures relies on fitting models saturated for the relationship between these factors (ie, we estimated a different hazard ratio for each combination of categories). Potential confounders were considered to be age at baseline (continuous), study area (only for JPHC‐I, ‐II, and JACC), body mass index (BMI, 14 to \<19, 19 to \<21, 21 to \<23, 23 to \<25, 25 to \<27, 27 to \<30 kg/m^2^, and missing), and vegetable and fruit intake (never, 1‐2 days/week, 3‐4 days/week, 5‐7 days/week, and missing). The study estimated two types of hazard ratios (HRs): Model 1, which adjusted for age and area; and Model 2, which adjusted for age, area, BMI, and vegetable and fruit intake. We further estimated HRs which excluded cases within two years of baseline (Model 3).

2.6. Estimation of summary effects by meta‐analysis {#cam42514-sec-0008}
---------------------------------------------------

Because the effects of smoking and alcohol in the previously described multivariable Cox models were estimated jointly, we used multivariate meta‐analysis[47](#cam42514-bib-0047){ref-type="ref"}, [48](#cam42514-bib-0048){ref-type="ref"} to account for the fact that estimates coming from the same study were correlated. More precisely, we conducted random effects multivariate analyses based on likelihood maximization.[47](#cam42514-bib-0047){ref-type="ref"} Firth correction was used to deal with perfect prediction, that is, the fact that there might be no cases for some combinations of risk factor categories.

2.7. Measures of interaction {#cam42514-sec-0009}
----------------------------

The interaction of two risk factors refers to the fact that the effect of exposure to one factor might be modified by exposure to the second factor. In accordance with current interpretation of what a *modification* of the effect represents (which might depend on available knowledge on the biological mechanisms underlying the effects of the factors), two main types of interaction can be defined, an additive interaction and a multiplicative interaction. To explain these concepts, consider two binary risk factors, E1 and E2, and RR~10~, RR~01~, and RR~11~, the relative risks corresponding respectively to exposure to E1 only, E2 only, and to the combined exposure to E1 and E2 (note that we can extend this notation with RR~00~ = 1 corresponding to the relative risk for the nonexposed). Now say that RR~10~ = 2 and RR~01~ = 3. The additivity of the effects of the factors would correspond to the situation where RR~11~ = 4, that is, RR~11~ − RR~10~ = RR~01~ − 1, whereas multiplicativity would correspond to the situation where RR~11~ = 6, that is, RR~11~ = RR~10~ × RR~01~. According to the theory of how factors interact (at the biological level) to increase the risk of disease occurrence, we might understand "effect measure modification" as expressing a departure from multiplicativity (ie, RR~11~ $\neq$ RR~10~ × RR~01~) or, and more commonly in the epidemiological context, as expressing a departure from additivity (ie, RR~11~ − RR~10~ $\neq$ RR~01~ − 1).

From a computational point of view, multiplicative interaction can usually be assessed very easily because commonly used models (logistic regression, Poisson regression, Cox model) specify a multiplicative relationship between the factors. Consequently, multiplicative interaction can be assessed through the *interaction term* included between the factors in the formula of the model. In the case of additive interaction, we calculated in this work three commonly used measures, namely the relative excess risk due to interaction, RERI = RR~11~ − RR~10~ − RR~01~ + 1; the synergy index, Syn = (RR~11~ − 1)/\[(RR~10~ − 1) + (RR~01~ − 1)\]; and the attributable proportion, AP = (RR~11~ − RR~10~ − RR~01~ + 1)/RR~11~.[49](#cam42514-bib-0049){ref-type="ref"} RERI \> 0, Syn \> 1, and AP \> 0 means positive (super‐additive) interaction.

In the case of categorical variables with more than two categories, we considered category by category interactions; that is, if E1 had N1 categories and E2 had N2 categories, the interaction measures between exposure to category $i\,(2 \leq i \leq N_{1})$ of E1 and to category $j\,(2 \leq j \leq N_{2})$ of E2 were based on the preceding formulas, replacing $\text{RR}_{10}$ by $\text{RR}_{i1}$, $\text{RR}_{01}$ by $\text{RR}_{1j}$, $\text{RR}_{11}$and by $\text{RR}_{\mathit{ij}}$.

2.8. Confidence interval estimation for the summary estimates {#cam42514-sec-0010}
-------------------------------------------------------------

For the summary (meta‐analytic) estimates of hazard ratios and multiplicative interactions, confidence intervals (CIs) were obtained by simple computation on the basis that these quantities were monotonous transformations of linear combinations of the estimated summary coefficients.

For the summary measures of additive interactions, CIs were obtained by Monte Carlo simulation (sample n = 1 000 000) in the multivariate distribution of summary coefficients, assuming that this distribution is a multivariate normal.

2.9. Population attributable fractions {#cam42514-sec-0011}
--------------------------------------

Population attributable fractions (PAFs) were obtained by using the distribution of exposure to smoking and drinking in the study population and the summary hazard ratios of the fully adjusted model (Model 2).

PAFs for two the dichotomous exposures (E1, E2) were calculated by the following formulas:$$\begin{matrix}
{\text{PAF}\left( {E1} \right):} \\
{\quad\frac{p_{10} \ast \left( {\text{RR}_{10} - 1} \right) + p_{11} \ast \left( {\text{RR}_{11} - \text{RR}_{01}} \right)}{1 + \left\lbrack {p_{10} \ast \left( {\text{RR}_{10} - 1} \right) + p_{01} \ast \left( {\text{RR}_{01} - 1} \right) + p_{11} \ast \left( {\text{RR}_{11} - 1} \right)} \right\rbrack}} \\
 \\
\end{matrix}$$ $$\begin{matrix}
{\text{PAF}\left( {E2} \right):} \\
{\quad\frac{p_{01} \ast \left( {\text{RR}_{01} - 1} \right) + p_{11} \ast \left( {\text{RR}_{11} - \text{RR}_{10}} \right)}{1 + \left\lbrack {p_{10} \ast \left( {\text{RR}_{10} - 1} \right) + p_{01} \ast \left( {\text{RR}_{01} - 1} \right) + p_{11} \ast \left( {\text{RR}_{11} - 1} \right)} \right\rbrack}} \\
 \\
\end{matrix}$$ $$\begin{matrix}
{\text{PAF}\left( {E1 + E2} \right):} \\
{\quad\frac{p_{10} \ast \left( {\text{RR}_{10} - 1} \right) + p_{01} \ast \left( {\text{RR}_{01} - 1} \right) + p_{11} \ast \left( {\text{RR}_{11} - 1} \right)}{1 + \left\lbrack {p_{10} \ast \left( {\text{RR}_{10} - 1} \right) + p_{01} \ast \left( {\text{RR}_{01} - 1} \right) + p_{11} \ast \left( {\text{RR}_{11} - 1} \right)} \right\rbrack}} \\
 \\
\end{matrix}$$

Similarly, PAFs for the two categorical exposures with three levels each (numbered 1 to 3) were calculated by the following formulas:$$\text{PAF}\left( {E1} \right):\frac{\sum_{i = 1}^{3}\sum_{j = 1}^{3}p_{\mathit{ij}}\left( {\text{RR}_{\mathit{ij}} - \text{RR}_{1j}} \right)}{1 + \sum_{i = 1}^{3}\sum_{j = 1}^{3}p_{\mathit{ij}}\left( {\text{RR}_{\mathit{ij}} - \text{RR}_{11}} \right)}$$ $$\text{PAF}\left( {E2} \right):\frac{\sum_{i = 1}^{3}\sum_{j = 1}^{3}p_{\mathit{ij}}\left( {\text{RR}_{\mathit{ij}} - \text{RR}_{i1}} \right)}{1 + \sum_{i = 1}^{3}\sum_{j = 1}^{3}p_{\mathit{ij}}\left( {\text{RR}_{\mathit{ij}} - \text{RR}_{11}} \right)}$$ $$\text{PAF}\left( {\text{E1} + \text{E2}} \right):\frac{\sum_{i = 1}^{3}\sum_{j = 1}^{3}p_{\mathit{ij}}\left( {RR_{\mathit{ij}} - RR_{11}} \right)}{1 + \sum_{i = 1}^{3}\sum_{j = 1}^{3}p_{\mathit{ij}}\left( {RR_{\mathit{ij}} - RR_{11}} \right)}$$where RR_11 = 1 is the relative risk in the reference category of exposure to both factors.

3. RESULTS {#cam42514-sec-0012}
==========

The present pooled analysis included eight cohort studies, comprising 162 826 male subjects with 954 incident esophageal cancer cases during 2 053 871 person‐years of follow‐up (average follow‐up 12.6 years) (Table [2](#cam42514-tbl-0002){ref-type="table"}). At baseline, the proportion of ever smokers and ever drinkers was 60.6% and 78.5%, respectively. Almost half of subjects (49.1%) experienced both cigarette smoking and alcohol drinking. Cumulative smoking and amount of alcohol drinking were evaluated in five cohort studies (JPHC‐II, JACC, MIYAGI, OHSAKI, and TAKAYAMA). The proportion of subjects with heaviest smoking and drinking (more than 40 pack‐years of smoking and consumption of 46 g or more ethanol a day) was 8.1% (Table S2).

###### 

Characteristics

  Characteristics of the cohort studies   Characteristics of subjects in the present study                                                                                                                                                                                                          
  --------------------------------------- ------------------------------------------------------------------------------------------------------------- -------- ----------- --------- ----- --------------------------------------------------------------- ------ ------ ------- ------ --------- -----
  JPHC‐I                                  Japanese residents of 5 public health center areas in Japan                                                   40‐59    1990        61 595    82%   Cancer registries and death certificates                        2009   17.5   40‐59   17.3   20 258    144
  JPHC‐II                                 Japanese residents of 6 public health center areas in Japan                                                   40‐69    1993‐1994   78 825    80%   Cancer registries and death certificates                        2007   13.0   40‐69   12.5   29 188    181
  JACC                                    Residents from 45 areas throughout Japan                                                                      40‐79    1988‐1990   110 585   83%   Cancer registries (selected areas: 24) and death certificates   2009   13.0   40‐79   13.1   25 547    128
  MIYAGI                                  Residents of 14 municipalities in Miyagi Prefecture, Japan                                                    40‐64    1990        47 605    92%   Cancer registries and death certificates                        2007   15.6   40‐64   15.3   22 908    167
  OHSAKI                                  Beneficiaries of National Health Insurance among residents of 14 municipalities in Miyagi Prefecture, Japan   40‐79    1994        54 996    95%   Cancer registries and death certificates                        2006   8.9    40‐79   8.8    22 516    154
  3‐pref MIYAGI                           Residents of 3 municipalities in Miyagi Prefecture, Japan                                                     40‐98    1984        31 345    94%   Cancer registries and death certificates                        1992   7.4    40‐98   7.3    12 400    54
  3‐pref AICHI                            Residents of 2 municipalities in Aichi Prefecture, Japan                                                      40‐103   1985        33 529    90%   Cancer registries and death certificates                        2000   11.5   40‐97   11.2   15 582    59
  TAKAYAMA                                Residents of Takayama city in Gifu Prefecture, Japan                                                          35‐      1992        31 552    85%   Cancer registry and death certificate                           2008   13.6   35‐98   13.2   14 427    67
  Total                                                                                                                                                                      450 032                                                                                               12.6   162,826   954

Abbreviations: JACC, The Japan Collaborative Cohort Study; JPHC, Japan Public Health Center‐based Prospective Study; MIYAGI, The Miyagi Cohort Study; OHSAKI, Ohsaki Cohort Study; 3‐pref MIYAGI, The Three Prefecture Cohort Miyagi; 3‐pref AICHI, The Three Prefecture Cohort Aichi; TAKAYAMA, The Takayama Study.

John Wiley & Sons, Ltd

Esophageal cancer risk of smoking status, drinking status, and their interactions are shown in Table [3](#cam42514-tbl-0003){ref-type="table"}. In the age‐ and area‐adjusted model (model 1), HRs and their 95% CIs of cigarette smoking, alcohol drinking, and their combination were 2.92 (1.59‐5.36), 2.73 (1.78‐4.18), and 8.86 (4.82‐16.30), respectively. A statistically significant and positive interaction in the additive scale was observed with an RERI of 4.21 (2.26‐8.13), synergy of 2.16 (1.83‐2.77), and AP of 0.48 (0.40‐0.54). When the interaction was evaluated multiplicatively, the interaction of smoking and alcohol was 1.11 (0.74‐1.69). The direction of multiplicative interaction was the same as that for additive interaction, but the magnitude was small and without statistical significance. The multivariate‐adjusted HRs and HRs with the exclusion of early cases were similar to those in model 1.

###### 

Cigarette smoking status, alcohol drinking status, and their interaction for the risk of esophageal cancer

  Cigarette smoking status   Alcohol drinking status      Model 1   Model 2        Model 3                         
  -------------------------- ---------------------------- --------- -------------- --------- -------------- ------ --------------
  Never                      Never                        1         (reference)    1         (reference)    1      (reference)
  Ever                       Never                        2.92      (1.59‐5.36)    2.77      (1.52‐5.06)    2.96   (1.75‐4.99)
  Never                      Ever                         2.73      (1.78‐4.18)    2.76      (1.81‐4.19)    2.79   (1.93‐4.04)
  Ever                       Ever                         8.86      (4.82‐16.30)   8.32      (4.56‐15.18)   8.54   (4.90‐14.87)
                             Multiplicative interaction   1.11      (0.74‐1.69)    1.09      (0.73‐1.63)    1.03   (0.76‐1.41)
                             RERI                         4.21      (2.26‐8.13)    3.79      (2.04‐7.28)    3.79   (2.00‐7.25)
                             AP                           0.48      (0.40‐0.54)    0.46      (0.38‐0.52)    0.44   (0.37‐0.51)
                             Synergy                      2.16      (1.83‐2.77)    2.07      (1.77‐2.65)    2.01   (1.75‐2.36)

Model 1: Adjusted for age and area

Model 2: Adjusted for age, area, body mass index, vegetables and fruit intake

Model 3: Adjusted for age, area, body mass index, vegetables and fruit intake. Esophageal cancer arising within 2 years of the start of follow‐up was excluded.

Abbreviations: AP, attributable proportion; CI, confidence interval; HR, hazard ratio; RERI, relative excess risk due to interaction.
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Cumulative smoking and amount of alcohol drinking and their interaction for the risk of esophageal cancer is shown in Table [4](#cam42514-tbl-0004){ref-type="table"}. Compared to people who did not smoke and drank less than 23 g of alcohol a day, those who drank 46 g or more had an HR of 5.29 (2.90‐9.65) and those with more than 40 pack‐years had an HR of 4.80 (2.97‐7.77) in the age‐ and area‐adjusted model (model 1). These HRs were increased by alcohol consumption in each cumulative smoking level. All interactions between alcohol drinking levels and cumulative smoking with multiplicative evaluation were negative in direction and lacked statistical significance. On the other hand, additively evaluated interactions were positive for risk. In particular, the additive interaction among those with a combination of more than 40 pack‐years of smoking and consumption of 46 g or more of alcohol a day was significantly positive, with an RERI of 8.47 (2.20‐16.16), synergy of 2.05 (1.20‐3.43), and AP of 0.48 (0.16‐0.67). Similar HRs, multiplicative interactions and additive interactions were seen in model 2 (multivariate‐adjusted model) and model 3 (exclusion of early cases).

###### 

Cumulative cigarette smoking, amount of alcohol drinking, and their interaction for the risk of esophageal cancer

  Pack‐years   Amount of alcohol drinking (g/day)   HR      95% CI          Multiplicative interaction   RERI                 AP                  Synergy
  ------------ ------------------------------------ ------- --------------- ---------------------------- -------------------- ------------------- ------------------
  Model 1                                                                                                                                         
  0            \<23                                 1       (reference)                                                                            
  0            ≥23, \<46                            3.43    (1.73‐6.79)                                                                            
  0            ≥46                                  5.29    (2.90‐9.65)                                                                            
  ≤40          \<23                                 2.75    (1.57‐4.80)                                                                            
  ≤40          ≥23, \<46                            7.81    (4.60‐13.24)    0.83 (0.38‐1.80)             2.63 (−0.36‐5.94)    0.34 (−0.05‐0.58)   1.63 (0.94‐3.05)
  ≤40          ≥46                                  10.92   (6.50‐18.35)    0.75 (0.35‐1.60)             3.88 (−1.22‐9.75)    0.36 (−0.14‐0.62)   1.64 (0.86‐3.04)
  \>40         \<23                                 4.80    (2.97‐7.77)                                                                            
  \>40         ≥23, \<46                            12.96   (6.16‐27.26)    0.79 (0.30‐ 2.04)            5.73 (−1.25‐18.58)   0.44 (−0.17‐0.73)   1.92 (0.84‐4.25)
  \>40         ≥46                                  17.56   (11.45‐26.92)   0.69 (0.32‐ 1.48)            8.47 (2.20‐16.16)    0.48 (0.16‐0.67)    2.05 (1.20‐3.43)
  Model 2                                                                                                                                         
  0            \<23                                 1       (reference)                                                                            
  0            ≥23, \<46                            3.71    (1.86‐7.37)                                                                            
  0            ≥46                                  5.56    (2.99‐10.33)                                                                           
  ≤40          \<23                                 2.66    (1.55‐4.56)                                                                            
  ≤40          ≥23, \<46                            8.02    (4.78‐13.46)    0.78 (0.36‐1.68)             2.30 (−0.84‐5.49)    0.30 (−0.12‐0.56)   1.53 (0.88‐2.84)
  ≤40          ≥46                                  10.35   (6.25‐17.13)    0.70 (0.33‐1.47)             3.13 (−2.03‐8.52)    0.30 (0.24‐0.59)    1.50 (0.78‐2.78)
  \>40         \<23                                 4.84    (3.03‐7.72)                                                                            
  \>40         ≥23, \<46                            12.58   (6.12‐25.86)    0.70 (0.28‐ 1.73)            5.03 (−1.47‐16.53)   0.40 (−0.20‐0.69)   1.77 (0.81‐3.70)
  \>40         ≥46                                  16.85   (11.07‐25.66)   0.63 (0.30‐ 1.32)            7.46 (1.41‐14.52)    0.44 (0.10‐0.64)    1.89 (1.12‐3.09)
  Model 3                                                                                                                                          
  0            \<23                                 1       (reference)                                                                            
  0            ≥23, \<46                            3.90    (1.84‐8.27)                                                                            
  0            ≥46                                  5.62    (2.94‐10.76)                                                                           
  ≤40          \<23                                 2.77    (1.53‐5.01)                                                                            
  ≤40          ≥23, \<46                            8.08    (4.61‐14.15)    0.75 (0.32‐ 1.72)            2.40 (−1.13‐5.84)    0.30 (−0.14‐0.57)   1.51 (0.86‐2.97)
  ≤40          ≥46                                  10.53   (6.04‐18.38)    0.68 (0.32‐ 1.42)            3.14 (−1.70‐8.48)    0.30 (−0.19‐0.57)   1.49 (0.82‐2.64)
  \>40         \<23                                 5.16    (3.14‐8.50)                                                                            
  \>40         ≥23, \<46                            13.65   (6.66‐27.99)    0.68 (0.27‐ 1.68)            5.58 (−1.16‐17.43)   0.41 (−0.14‐0.69)   1.79 (0.86‐3.60)
  \>40         ≥46                                  17.51   (11.04‐27.77)   0.60 (0.29‐ 1.26)            7.72 (1.71‐15.29)    0.44(0.12‐ 0.63)    1.88 (1.15‐2.99)

Model 1; Adjusted for age and area.

Model 2; Adjusted for age, area, body mass index, vegetables and fruit intake.

Model 3; Adjusted for age, area, body mass index, vegetables and fruit intake. Esophageal cancer arising within 2 years of the start of follow‐up was excluded.

Abbreviations: AP, attributable proportion; CI, confidence interval; HR, hazard ratio; RERI, relative excess risk due to interaction.
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The PAF of esophageal cancer incidence from cigarette smoking and alcohol drinking was estimated (Table [5](#cam42514-tbl-0005){ref-type="table"}). PAF from ever smoking, ever drinking, and the combination of both ever smoking and ever drinking was 55.4%, 61.2%, and 81.4%, respectively. Similarly, PAF from cumulative smoking, amount of alcohol drinking, and their combination was 49.7%, 59.5%, and 84.0%, respectively.

###### 

Population attributable fraction of cigarette smoking and alcohol drinking for esophageal cancer incidence

         Cigarette smoking only   Alcohol drinking only   Cigarette smoking and alcohol
  ------ ------------------------ ----------------------- -------------------------------
  PAF1   0.554                    0.612                   0.814
  PAF2   0.497                    0.595                   0.840

PAF1 was calculated using person‐years and HRs estimated by cigarette smoking status and alcohol drinking status.

PAF2 was calculated using person‐years and HRs estimated by cumulative smoking (pack‐years) and amount of alcohol drinking status.

HRs were adjusted for age, area, body mass index, vegetables and fruit intake.

Abbreviation: PAF; population attributable fraction

John Wiley & Sons, Ltd

4. DISCUSSION {#cam42514-sec-0013}
=============

We conducted a pooled analysis of eight large population‐based cohort studies to quantitatively estimate esophageal cancer risk of cigarette smoking and alcohol consumption among Japanese males. To our knowledge, this pooled study represents the largest evaluation of the magnitude of the impact of cigarette smoking and alcohol drinking for esophageal cancer. In addition, it is the first pooled analysis of population‐based cohort studies to evaluate the interaction of cigarette smoking and alcohol drinking in both multiplicative and additive scales.

Cigarette smoking alone was associated with a 2.77 times' higher risk of esophageal cancer in this study. Our previous meta‐analysis of published articles focusing on Japanese populations showed a consistent summary estimate of 3.01.[50](#cam42514-bib-0050){ref-type="ref"} In addition, pack‐years showed clear dose‐response relationships with esophageal cancer risk. Likewise, alcohol drinking alone was associated with a 2.76 times' higher risk of esophageal cancer, which was consistent with our previous meta‐analysis.[51](#cam42514-bib-0051){ref-type="ref"} A clear dose‐response relationship was shown between the amount of alcohol drinking and esophageal cancer risk. Esophageal cancer control might legitimately take account of not only the significance of risk by cigarette smoking and alcohol drinking, but also the magnitude of these risks.

This study assessed the interaction between cigarette smoking and alcohol drinking. When the interaction was assessed multiplicatively, the interaction in ever smoking and ever drinking was non‐significant and slightly positive, whereas the interaction in smoking of more than 40 pack‐years and drinking 46 or more grams of ethanol a day was non‐significant and negative. Therefore, in this study, we did not observe any evidence of multiplicative interaction. In other words, the magnitude of combination effect of smoking and drinking by dichotomous and trichotomous categorization was compatible with what we expected from multiplicative model without multiplicative interaction. In contrast, when we evaluate those interactions in additive scale, the interactions were consistently positive and statistically significant. In addition, magnitude of interaction in additive scale showed dose‐response relationship with cigarette smoking and alcohol drinking. This consistency, dose‐response relationship, and biological plausibility support the idea that cigarette smoking and alcohol drinking interacts in an additive way.

Additive interaction has an interpretation in terms of the presence of biological interaction between the factors. Various gene alterations for esophageal cancer carcinogenesis were reported. Recent study suggested that distributions of gene mutations in physiologically normal epithelia and esophageal squamous cell carcinoma were different.[52](#cam42514-bib-0052){ref-type="ref"} Thus, accumulation of non‐specific gene alteration in normal esophageal mucosa and esophageal cancer‐specific gene alteration might be necessary for esophageal carcinogenesis. When multistage carcinogenesis theory was assumed, accumulation of non‐specific gene alteration might occur as first stage, then cancer‐specific gene alteration as second stage might be required in esophageal carcinogenesis. Both cigarette smoking and alcohol drinking might mainly affect the first stage because of the additivity of their interaction and long duration of their exposure. Furthermore, cigarette smoking and alcohol drinking were associated with cancer‐specific gene alteration.[52](#cam42514-bib-0052){ref-type="ref"}, [53](#cam42514-bib-0053){ref-type="ref"}, [54](#cam42514-bib-0054){ref-type="ref"} The evidence might support the significant positive interaction in additive scale because both cigarette smoking and alcohol drinking might partly play a role in the second stage.

Results for PAF suggested that cigarette smoking and alcohol drinking cause more than 80% of esophageal cancer. Furthermore, smoking only or alcohol drinking only might cause around 50% and 60% of esophageal cancer, respectively. Simple summation of PAF from smoking and drinking was more than 100% because of the interaction between cigarette smoking and alcohol drinking. It just means that in some individuals, the presence of both factors is required for the cancer to occur.[55](#cam42514-bib-0055){ref-type="ref"} As such, this is a quantity of interest to public health practitioners because acting on only one risk factor can not only prevent cases associated with exposure to this factor alone but also cases that need both exposures to happen. This also finds a practical translation in PAF estimations: in the absence of additive interaction, the PAF for a modification of exposure to both factors is equal to the sum of the PAFs for the modification of exposure to each factor separately whereas it is less than this sum in case of additive interaction. Thus, both quitting smoking and abstaining from alcohol would be the best way to reduce esophageal cancer incidence. However, either tobacco control or restriction of alcohol would likely provide an adequate degree of impact and might therefore be an option. Indeed, the impact of intervention might be an important point in planning public health policy to achieve esophageal cancer control with fewer costs.

The study has several strengths. First, it estimated interactions by both multiplicative and additive scales. Second, it pooled eight large population‐based cohort studies in Japan. The magnitude of risks and interactions would therefore be valid and applicable to Japanese males. Several limitations should also be mentioned. First, female subjects were excluded from the study. Age‐adjusted esophageal cancer incidence rate per 100,000 Japanese males and females in 2009 was 17.1 and 2.8, respectively.[56](#cam42514-bib-0056){ref-type="ref"} Moreover, the prevalence of smoking and habitual drinking among females (9.0% and 9.3%, respectively) were much lower than those among males (28.2% and 42.9%, respectively).[57](#cam42514-bib-0057){ref-type="ref"} Accordingly, any finding that the magnitude of relative risks and interaction in females were similar to those in males would suggest that cigarette smoking, alcohol drinking and their interaction might have less influence on esophageal cancer than in the present study.

In conclusion, we confirmed that cigarette smoking and alcohol drinking were risk factors for esophageal cancer in Japanese males. A significant positive additive interaction between cigarette smoking and alcohol drinking was found, although significant interaction on a multiplicative scale was not observed. PAF of cigarette smoking, alcohol drinking and their combination suggest that either quitting smoking or drinking alone might make a major contribution to esophageal cancer prevention.
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